Why Filana Therapeutics, Inc.’s (FLNA) Stock Is Up 5.30%
As of Monday, June 08, Filana Therapeutics, Inc.’s FLNA share price has surged by 5.30%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jenna Brashear
Rosalio Madrigal
Cynthia McLaughlin
| Share Statistics | FLNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $21.4 | $447.9 | 11% |
|
| Shares Out (Mil) | 48.5 | 46.7 | 47% |
|
| Institutional Ownership | 90.1% | 80.9% | 58% |
|
| Float (Mil) | 46.9 | 46.8 | 45% |
|
| Beta | -0.45 | 0.74 | 2% |
|
| Avg Daily Volume (000s) | 499 | 342 | 57% |
|
| Price Change (52-week) |
(87.0%) | 54.7% | 6% |
|
| Growth | FLNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (70.6%) | (1.6%) | 4% |
|
| EPS (5yr) | (50.6%) | 15.0% | 3 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (17.6%) | (15.1%) | 40% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | FLNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $303 | na |
|
| Net Income (TTM) (Mil) | ($42) | ($10) | 17% |
|
| EPS (TTM) | ($0.873) | ($0.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($7) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($25) | $408 | 1% |
|
| Valuation | FLNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.37 | 2.19 | 8% |
|
| P/E | na | 22.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | FLNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (36.7%) | (22.7%) | 14% |
|
| ROE | (60.5%) | (25.0%) | 13% |
|
| Liabilities to Assets | 42.1% | 31.8% | 33% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 11/13/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 2.6% |
| +/- S&P 500: | -4.8 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors